Literature DB >> 35809178

Progress in Mechanism of Astragalus membranaceus and Its Chemical Constituents on Multiple Sclerosis.

Yong Peng1, Xiang Deng2, Shan-Shan Yang2, Wei Nie2, Yan-Dan Tang2.   

Abstract

The primary chemical components of Astragalus membranaceus include polysaccharides, saponins, flavonoids, and amino acids. Recent studies have shown that Astragalus membranaceus has multiple functions, including improving immune function and exerting antioxidative, anti-radiation, anti-tumor, antibacterial, antiviral, and hormone-like effects. Astragalus membranaceus and its extracts are widely used in clinical practice because they have obvious therapeutic effects against various autoimmune diseases and relatively less adverse reaction. Multiple sclerosis (MS) is an autoimmune disease of central nervous system (CNS), which mainly caused by immune disorder that leads to inflammatory demyelination, inflammatory cell infiltration, and axonal degeneration in the CNS. In this review, the authors analyzed the clinical manifestations of MS and experimental autoimmune encephalomyelitis (EAE) and focused on the efficacy of Astragalus membranaceus and its chemical components in the treatment of MS/EAE.
© 2022. The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Astragalus membranaceus; chemical components; experimental autoimmune encephalomyelitis; immunoregulation; multiple sclerosis

Year:  2022        PMID: 35809178     DOI: 10.1007/s11655-022-3535-6

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  15 in total

Review 1.  Multiple sclerosis: risk factors, prodromes, and potential causal pathways.

Authors:  Sreeram V Ramagopalan; Ruth Dobson; Ute C Meier; Gavin Giovannoni
Journal:  Lancet Neurol       Date:  2010-07       Impact factor: 44.182

2.  Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab.

Authors:  Reuben Mari Valenzuela; John H Pula; Dennis Garwacki; John Cotter; Jorge C Kattah
Journal:  J Neurol Sci       Date:  2014-03-11       Impact factor: 3.181

3.  Traditional Chinese medicine for Parkinson's disease in China and beyond.

Authors:  Yan Wang; Xian-ming Lin; Guo-Qing Zheng
Journal:  J Altern Complement Med       Date:  2011-05-06       Impact factor: 2.579

4.  Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.

Authors:  Neil Scolding; David Barnes; Sarah Cader; Jeremy Chataway; Abhijit Chaudhuri; Alasdair Coles; Gavin Giovannoni; David Miller; Waqar Rashid; Klaus Schmierer; Abdullah Shehu; Eli Silber; Carolyn Young; John Zajicek
Journal:  Pract Neurol       Date:  2015-06-22

5.  Progressive multifocal leukoencephalopathy after interferon beta-1a monotherapy.

Authors:  Helmar C Lehmann; Klaus Krüger; Gereon R Fink; Michael Schroeter
Journal:  J Neurol       Date:  2015-01-13       Impact factor: 4.849

Review 6.  Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change.

Authors:  Hans-Peter Hartung; Jonas Graf; Orhan Aktas; Jan Mares; Michael H Barnett
Journal:  Curr Opin Neurol       Date:  2019-06       Impact factor: 5.710

Review 7.  Persistence and pathogenesis of the neurotropic polyomavirus JC.

Authors:  Hassen S Wollebo; Martyn K White; Jennifer Gordon; Joseph R Berger; Kamel Khalili
Journal:  Ann Neurol       Date:  2015-03-06       Impact factor: 10.422

Review 8.  Advances in physical rehabilitation of multiple sclerosis.

Authors:  Diego Centonze; Letizia Leocani; Peter Feys
Journal:  Curr Opin Neurol       Date:  2020-06       Impact factor: 5.710

Review 9.  Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use.

Authors:  M X Min; D I Weinberg; R P McCabe
Journal:  J Clin Pharm Ther       Date:  2014-01-20       Impact factor: 2.512

Review 10.  Natural killer cells in multiple sclerosis: A review.

Authors:  Max Mimpen; Joost Smolders; Raymond Hupperts; Jan Damoiseaux
Journal:  Immunol Lett       Date:  2020-02-27       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.